



Journal of the British Cardiovascular Society

Guidelines for Authors and Reviewers

Full instructions are available online at <http://heart.bmj.com/fora>. Articles must be submitted electronically <http://heart.bmj.com/submit>. Authors retain copyright but are required to grant *Heart* an exclusive licence to publish <http://heart.bmj.com/fora/licence.dtl>

Editorial Office

Heart, BMJ Publishing Group
BMA House, Tavistock Square
London WC1H 9JR, UK
T: +44 (0) 20 7383 6622
F: +44 (0) 20 7383 6668
E: heartjournal@bmj.com

Twitter: @Heart_BMJ

ISSN: 1355-6037 (print)
ISSN: 1468-201X (online)

Impact factor: 5.693

Disclaimer: *Heart* is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the British Cardiovascular Society. The owners grant editorial freedom to the Editor of *Heart*. *Heart* follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

Heart is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, the British Cardiovascular Society or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of *Heart* or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2017 BMJ Publishing Group Ltd & British Cardiovascular Society. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission.

Heart is published by BMJ Publishing Group Ltd, typeset by Nova Techset Private Limited, Bengaluru & Chennai, India and printed in the UK on acid-free paper.

Heart (ISSN No 1355-6037) is published semi-monthly by BMJ Publishing Group and distributed in the in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: Send address changes to *Heart*, Air Business Ltd, c/o Worldnet Shipping Inc, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA



Heartbeat

327 Heartbeat: Diabetes and heart failure
C M Otto

Editorials

329 Estimating cancer risk from invasive cardiac procedures in children
V B Ladouceur, P R Lawler

331 The long and unfinished journey of hyperglycaemia and heart failure research
K Rahimi

333 Understanding sudden death risk in tetralogy of Fallot: from bedside to bench
S Seslar, M Robinson

Review

335 Graphics and statistics for cardiology: survival analysis
S May, B McKnight

Congenital heart disease

341 Survival adjusted cancer risks attributable to radiation exposure from cardiac catheterisations in children
R W Harbron, C-L Chapple, J J O'Sullivan, K E Best, A Berrington de González, M S Pearce

347 Proarrhythmic remodelling of the right ventricle in a porcine model of repaired tetralogy of Fallot
D Benoist, V D Dubes, F Roubertie, S H Gilbert, S Charron, M Constantin, D Elbes, D Vieillot, B Quesson, H Cochet, M Haïssaguerre, C Rooryck, P Bordachar, J-B Thambo, O Bernus

Heart failure and cardiomyopathies

355 Contemporary risk estimates of three HbA_{1c} variables in relation to heart failure following diagnosis of type 2 diabetes
S Skrtic, C Cabrera, M Olsson, V Schneck, M Lind

Valvular heart disease

361 Pre-procedural dual antiplatelet therapy in patients undergoing transcatheter aortic valve implantation increases risk of bleeding
H Hioki, Y Watanabe, K Kozuma, Y Nara, H Kawashima, A Kataoka, M Yamamoto, K Takagi, M Araki, N Tada, S Shirai, F Yamanaka, K Hayashida, and on behalf of OCEAN-TAVI investigators

Arrhythmias and sudden death

368 Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomised clinical trial
J C Nielsen, A Johannessen, P Raatikainen, G Hindricks, H Walfridsson, S M Pehrson, A Englund, J Hartikainen, L S Mortensen, P S Hansen, for the MANTRA-PAF Investigators

377 Discovery of new biomarkers for atrial fibrillation using a custom-made proteomics chip
L Lind, J Sundström, M Stenemo, E Hagström, J Ärnlöv

Coronary artery disease

383 Cardiorespiratory fitness and exercise-induced ST segment depression in assessing the risk of sudden cardiac death in men
M J Hagnäs, T A Lakka, S Kurl, R Rauramaa, T H Mäkitallio, K Savonen, J A Laukkanen

Education in Heart

390 Mitochondrial disease and the heart
G Limongelli, D Masarone, G Pacileo

Image challenge

367 Postoperative dyspnoea
J R Sims, M Enriquez-Sarano, H I Michelena



This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://heart.bmj.com/site/about/guidelines.xhtml#open>



Member since 2008
JM00009

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics
www.publicationethics.org.uk



The online version of this article contains multiple choice questions hosted on BMJ Learning.